science
Vertex to Buy Crinetics for $10 Billion, Largest Deal in Its History
Vertex Pharmaceuticals announced it will buy Crinetics Pharmaceuticals for $10 billion, or $85 per share. The transaction marks Vertex's largest acquisition and adds a commercial drug for acromegaly plus a late-stage candidate for congenital adrenal hyperplasia.
StatAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Vertex Pharmaceuticals announced on July 6, 2026, that it will acquire Crinetics Pharmaceuticals for $10 billion. The deal values Crinetics at $85 per share and represents the largest acquisition in Vertex's history, @statnews reported. The purchase price reflects a 102% premium to Crinetics' closing stock price on Monday.
Crinetics shares rose 101% in after-hours trading, while Vertex shares fell 2%, according to Reuters. Crinetics markets Palsonify, a drug launched in 2025 that treats acromegaly, a rare endocrine disorder. The company is also developing a therapy for congenital adrenal hyperplasia that remains in late-stage trials, @statnews reported.
The boards of both companies approved the transaction. It is expected to close in the third quarter of 2026, Reuters and Bloomberg reported. The acquisition expands Vertex into endocrinology and adds medicines for acromegaly and other hormone disorders, Bloomberg reported.
Transparency
How sources framed this
These outlets didn't split into competing frames — coverage was uniform.
CorroborationModerate · 3 sources
